Biofrontera Q1 Revenues Up 17% to $10.1M, Gross Margin at 80%
Biofrontera reported Q1 product revenues of $10.1 million, up 17% year-over-year, with gross margin expanding to about 80% versus 62%. The company achieved near-zero operating cash burn, but recorded a $4.8 million net loss, noted a going concern risk and faces patent litigation expenses.
1. Q1 Financial Results
Biofrontera achieved product revenues of $10.1 million in Q1 2026, a 17% increase over Q1 2025, while gross margin expanded to approximately 80% from 62% in the prior year quarter.
2. Cash Flow and Net Loss
The company reported near-zero cash usage in operations versus $4.1 million used in Q1 2025, yet posted a net loss of $4.8 million, or $0.41 per share, driven by higher operating expenses.
3. Clinical Development and NDA Plans
Positive Phase 3 clinical results for actinic keratosis on extremities, neck and trunk support a supplemental NDA submission, and the firm expects to proceed with Phase III acne trials pending FDA discussions.
4. Risks and Compliance
Operating expenses rose to $14.4 million from $13.1 million due to increased SG&A and legal costs, a going concern qualification remains in effect, and the company has regained Nasdaq bid-price compliance.